BUDGET IMPACT MODEL (BIM) OF BELANTAMAB MAFODOTIN (BELAMAF) IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE (BVD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE UNITED STATES (US)
Author(s)
Natalie Boytsov, PhD1, Molly Purser, MBA, PhD1, Richard Zur, PhD2, Yevgeniy SAMYSHKIN, MSc3, Nicole Niehoff, PhD4, Teresa Palumbo, DMSc, PA-C5, Torey Batts, PhD1, Michelle Kamdar, PharmD1, James Osborne, PharmD1, Cheryl Ferrufino, BA2;
1GSK, Upper Providence, PA, USA, 2IQVIA, Falls Church, VA, USA, 3GSK, London, United Kingdom, 4GSK, Durham, NC, USA, 5GSK, New York City, NY, USA
1GSK, Upper Providence, PA, USA, 2IQVIA, Falls Church, VA, USA, 3GSK, London, United Kingdom, 4GSK, Durham, NC, USA, 5GSK, New York City, NY, USA
OBJECTIVES: With the recent approval of BVd for RRMM in the US, this analysis aimed to assess the budgetary impact of BVd on payer formularies.
METHODS: A comparative cost-determination framework estimated the net budget impact of adding BVd to payer formularies for patients with RRMM who received ≥2 prior therapy lines (3L+) including a proteasome inhibitor (PI) and immunomodulatory drug (IMD). Twelve comparators (anti-CD38/IMD/PI-containing triplets; chimeric antigen receptor T-cell [CAR-T] therapies, and bispecific antibodies [BsAbs]) were included; BVd adoption rate was assumed to be 12.0%/22.3%/33.1% in Years (Y) 1/2/3, and taken proportionally from all comparators except CAR-T/BsAb. Median progression-free survival, median overall survival, median duration of therapy, and median time to next treatment were input from published clinical trials for each included regimen and from the DREAMM-7/DREAMM-8 trials for BVd, daratumumab+Vd, and pomalidomide+Vd. Drug acquisition, administration, monitoring, grade ≥3 adverse event (grade ≥2 ocular events for BVd; grade ≥2 cytokine release syndrome for CAR-Ts/BsAbs), subsequent treatment, and end of life costs were modeled. Costs were inflated to 2025 US dollars using the latest available inflation rates as of April 2025. Results are reported from a commercial perspective for patients aged 18-64 years.
RESULTS: Among the hypothetical commercial population of 1,000,000 patients aged 18-64 years, 7/8/8 in Y1/2/3 had 3L+ RRMM and were newly eligible for BVd. In Y1, estimated total costs without BVd were $4,341,769; BVd uptake (projected uptake 1 patient) increased costs to $4,377,737 (+0.8%), with a per-member-per-month (PMPM) increase of $0.005. From Y1 to Y3, estimated total costs without BVd were $17,718,207; BVd uptake (projected uptake 3 patients at Y3) decreased costs by $435,779 (-2.5%) to $17,282,427 (-$0.01 PMPM).
CONCLUSIONS: Addition of BVd to formularies for 3L+ RRMM is a manageable financial consideration for payers, with negligible budget impact PMPM and modest budget saving by Y3. FUNDING: GSK (study 221158)
METHODS: A comparative cost-determination framework estimated the net budget impact of adding BVd to payer formularies for patients with RRMM who received ≥2 prior therapy lines (3L+) including a proteasome inhibitor (PI) and immunomodulatory drug (IMD). Twelve comparators (anti-CD38/IMD/PI-containing triplets; chimeric antigen receptor T-cell [CAR-T] therapies, and bispecific antibodies [BsAbs]) were included; BVd adoption rate was assumed to be 12.0%/22.3%/33.1% in Years (Y) 1/2/3, and taken proportionally from all comparators except CAR-T/BsAb. Median progression-free survival, median overall survival, median duration of therapy, and median time to next treatment were input from published clinical trials for each included regimen and from the DREAMM-7/DREAMM-8 trials for BVd, daratumumab+Vd, and pomalidomide+Vd. Drug acquisition, administration, monitoring, grade ≥3 adverse event (grade ≥2 ocular events for BVd; grade ≥2 cytokine release syndrome for CAR-Ts/BsAbs), subsequent treatment, and end of life costs were modeled. Costs were inflated to 2025 US dollars using the latest available inflation rates as of April 2025. Results are reported from a commercial perspective for patients aged 18-64 years.
RESULTS: Among the hypothetical commercial population of 1,000,000 patients aged 18-64 years, 7/8/8 in Y1/2/3 had 3L+ RRMM and were newly eligible for BVd. In Y1, estimated total costs without BVd were $4,341,769; BVd uptake (projected uptake 1 patient) increased costs to $4,377,737 (+0.8%), with a per-member-per-month (PMPM) increase of $0.005. From Y1 to Y3, estimated total costs without BVd were $17,718,207; BVd uptake (projected uptake 3 patients at Y3) decreased costs by $435,779 (-2.5%) to $17,282,427 (-$0.01 PMPM).
CONCLUSIONS: Addition of BVd to formularies for 3L+ RRMM is a manageable financial consideration for payers, with negligible budget impact PMPM and modest budget saving by Y3. FUNDING: GSK (study 221158)
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE264
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
SDC: Oncology